Clinical Trials
11
Active:1
Completed:8
Trial Phases
2 Phases
Phase 1:8
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 1
8 (72.7%)Phase 2
3 (27.3%)A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Healthy and Obese Subjects
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Gannex Pharma Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT06427590
- Locations
- 🇦🇺
Ascletis, Herston, Queensland, Australia
Drug Interaction Study of ASC42 With Atorvastatin
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Gannex Pharma Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05464628
- Locations
- 🇺🇸
ICON, San Antonio, Texas, United States
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
Phase 2
Active, not recruiting
- Conditions
- Non-alcoholic SteatohepatitisNon-alcoholic Fatty Liver Disease
- Interventions
- Drug: 2mg of ASC41Drug: 4mg of ASC41 (2 tablets of 2 mg ASC41)Drug: Placebo
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Gannex Pharma Co., Ltd.
- Target Recruit Count
- 183
- Registration Number
- NCT05462353
- Locations
- 🇨🇳
The affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: ASC61 400 mgDrug: ASC61 600 mgDrug: ASC61 200 mg 2Drug: ASC61 200 mg 1Drug: ASC61 300 mg
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Gannex Pharma Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05287399
- Locations
- 🇺🇸
California Cancer Associates for Research & Excellence (cCARE), San Marcos, California, United States
🇺🇸Nebraska Cancer Specialists, Omaha, Nebraska, United States
Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis
Phase 2
Completed
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Drug: ASC42 15 mgDrug: PlaceboDrug: ASC42 5 mgDrug: ASC42 10 mg
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Gannex Pharma Co., Ltd.
- Target Recruit Count
- 98
- Registration Number
- NCT05190523
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- Next
News
No news found